Title: R.E.D.U.C.E. trial: Is Less is Best?<br/>Author: Haney Mallemat<br/><a href='http://umem.org/profiles/faculty/785/'>[Click to email author]</a><hr/><p>
COPD treatment guidelines (e.g., GOLD) recommend 10-14 days of steroid therapy following a COPD exacerbation to prevent recurrences; the supporting data is weak.</p>
<p>
A recent noninferiority trial (<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2013%3B309(21)%3A2223-2231">here</a>) compared patients with a severe COPD exacerbation who received either a 5-day course (n=156) or 14-day course (n=155) of prednisone 40mg.</p>
<p>
The <strong>results</strong> were:</p>
<ul>
<li>
No significant reduction in time until the next exacerbation (primary end-point)</li>
<li>
No significant difference in mortality, incidence of mechanical ventilation, FEV1, or dyspnea scores (secondary end-points)</li>
</ul>
<p>
What you <strong>need to know</strong>:</p>
<ul>
<li>
This was a non-inferiority trial, which has limitations</li>
<li>
All subjects received broad-spectrum antibiotics and an initial dose of IV steroid</li>
<li>
Surprisingly, there were no differences between groups with respect to steroid complications (e.g., hyperglycemia, hypertension, etc.)</li>
</ul>
<p>
<u><strong>Bottom-line</strong></u><strong>: 5 days of prednisone may be as effective as 14-days for COPD exacerbations.</strong></p>
<fieldset><legend>References</legend>
<p>
<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=JAMA+2013%3B309(21)%3A2223-2231" style="font-size: 12px;">Leuppi, JD, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013 Jun 5;309(21):2223-31</a></p>
<p style="text-align: center;">
<strong style="font-size: 12px;">Follow me on Twitter (@criticalcarenow) or Google+ (+criticalcarenow)</strong></p>
</fieldset>